S&P 500   4,590.95 (+0.86%)
DOW   35,666.16 (+0.49%)
QQQ   383.74 (+0.98%)
AAPL   152.61 (+2.53%)
MSFT   323.73 (+0.17%)
FB   319.80 (+2.43%)
GOOGL   2,919.86 (-0.15%)
TSLA   1,070.03 (+3.10%)
AMZN   3,472.34 (+2.35%)
NVDA   248.15 (+1.49%)
BABA   169.91 (+0.40%)
NIO   40.55 (+3.15%)
CGC   13.05 (+2.11%)
GE   104.79 (+0.91%)
AMD   120.89 (-1.14%)
MU   69.44 (+1.76%)
T   25.62 (+2.23%)
F   16.95 (+9.28%)
ACB   6.94 (+1.46%)
DIS   170.11 (+0.33%)
PFE   43.17 (+0.47%)
BA   208.20 (+0.77%)
AMC   35.17 (+1.18%)
S&P 500   4,590.95 (+0.86%)
DOW   35,666.16 (+0.49%)
QQQ   383.74 (+0.98%)
AAPL   152.61 (+2.53%)
MSFT   323.73 (+0.17%)
FB   319.80 (+2.43%)
GOOGL   2,919.86 (-0.15%)
TSLA   1,070.03 (+3.10%)
AMZN   3,472.34 (+2.35%)
NVDA   248.15 (+1.49%)
BABA   169.91 (+0.40%)
NIO   40.55 (+3.15%)
CGC   13.05 (+2.11%)
GE   104.79 (+0.91%)
AMD   120.89 (-1.14%)
MU   69.44 (+1.76%)
T   25.62 (+2.23%)
F   16.95 (+9.28%)
ACB   6.94 (+1.46%)
DIS   170.11 (+0.33%)
PFE   43.17 (+0.47%)
BA   208.20 (+0.77%)
AMC   35.17 (+1.18%)
S&P 500   4,590.95 (+0.86%)
DOW   35,666.16 (+0.49%)
QQQ   383.74 (+0.98%)
AAPL   152.61 (+2.53%)
MSFT   323.73 (+0.17%)
FB   319.80 (+2.43%)
GOOGL   2,919.86 (-0.15%)
TSLA   1,070.03 (+3.10%)
AMZN   3,472.34 (+2.35%)
NVDA   248.15 (+1.49%)
BABA   169.91 (+0.40%)
NIO   40.55 (+3.15%)
CGC   13.05 (+2.11%)
GE   104.79 (+0.91%)
AMD   120.89 (-1.14%)
MU   69.44 (+1.76%)
T   25.62 (+2.23%)
F   16.95 (+9.28%)
ACB   6.94 (+1.46%)
DIS   170.11 (+0.33%)
PFE   43.17 (+0.47%)
BA   208.20 (+0.77%)
AMC   35.17 (+1.18%)
S&P 500   4,590.95 (+0.86%)
DOW   35,666.16 (+0.49%)
QQQ   383.74 (+0.98%)
AAPL   152.61 (+2.53%)
MSFT   323.73 (+0.17%)
FB   319.80 (+2.43%)
GOOGL   2,919.86 (-0.15%)
TSLA   1,070.03 (+3.10%)
AMZN   3,472.34 (+2.35%)
NVDA   248.15 (+1.49%)
BABA   169.91 (+0.40%)
NIO   40.55 (+3.15%)
CGC   13.05 (+2.11%)
GE   104.79 (+0.91%)
AMD   120.89 (-1.14%)
MU   69.44 (+1.76%)
T   25.62 (+2.23%)
F   16.95 (+9.28%)
ACB   6.94 (+1.46%)
DIS   170.11 (+0.33%)
PFE   43.17 (+0.47%)
BA   208.20 (+0.77%)
AMC   35.17 (+1.18%)

FDA grapples with timing of booster for J&J COVID-19 vaccine

Wednesday, October 13, 2021 | Matthew Perrone And Lauran Neergaard, Associated Press


In this Wednesday, March 3, 2021 file photo, a pharmacist holds a vial of the Johnson & Johnson COVID-19 vaccine at a hospital in Bay Shore, N.Y. Janssen Pharmaceuticals is a division of Johnson & Johnson. On Wednesday, Oct. 13, 2021, the Food and Drug Administration said it is wrestling with whether and when recipients of the single-shot Johnson & Johnson COVID-19 vaccine need another dose — at six months or as early as two months. (AP Photo/Mark Lennihan)

WASHINGTON (AP) — The Food and Drug Administration is wrestling with whether and when to offer a booster of the single-shot Johnson & Johnson COVID-19 vaccine — at six months or as early as two months. And a new study raises the prospect that using a different vaccine might give a better boost.

In an online review posted Wednesday, FDA scientists didn't reach a firm conclusion about whether there's enough evidence for J&J boosters, citing shortcomings with the company's data and little information on protection against the extra-contagious delta variant of the coronavirus.

The review comes ahead of meetings Thursday and Friday when an FDA advisory panel will recommend whether to back booster doses of both the J&J and Moderna vaccines. That's one step in the government's vaccine review process: Next week, the FDA will make a final decision on authorizing those boosters and then the Centers for Disease Control and Prevention will debate who actually should get them.

Adding to the complexity is whether it's OK to use a booster that's a different brand than someone's initial shots. Preliminary results of a U.S. government study suggest that mixing and matching boosters will work at least as well — and maybe far better for J&J recipients. Those people had a stronger immune response if they got either a Moderna or Pfizer shot as their booster than if they received another dose of the J&J vaccine, according to results posted online Wednesday. Mix-and-match is also up for discussion by the FDA panel this week.

Health authorities say all the vaccines used in the U.S. continue to provide strong protection against severe disease or death from COVID-19. But amid signs that protection against milder infections may be waning, the government already has cleared booster doses of the Pfizer vaccine for certain people starting at six months after their last shot.

Aiming for uniform recommendations, Moderna likewise asked the FDA to clear its booster dose at six months. But J&J complicated the decision by proposing a second shot over a range of two to six months.

FDA reviewers wrote that a study of the two-month booster plan suggests “there may be a benefit," while pointing to only small numbers of people who got another shot at six months instead.

Overall, the J&J vaccine "still affords protection against severe COVID-19 disease and death," the FDA's reviewers concluded. But data about its effectiveness “are consistently less” than the protection seen with Pfizer and Moderna shots.

For its part, J&J filed data with the FDA from a real-world study showing its vaccine remains about 80% effective against hospitalizations in the U.S.

J&J’s single-dose vaccine was highly anticipated for its one-and-done formulation. But its rollout was hurt by a series of troubles including manufacturing problems and some rare but serious side effects including a blood clot disorder and a neurological reaction called Guillain-Barre syndrome. In both cases, regulators decided the shot's benefits outweighed those risks.

Rival drugmakers Pfizer and Moderna have provided the vast majority of U.S. COVID-19 vaccines. More than 170 million Americans have been fully vaccinated with those companies’ two-dose shots while less than 15 million Americans got the J&J shot.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Should you invest $1,000 in Johnson & Johnson right now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)2.8$43.17+0.5%3.61%18.53Hold$44.00
Johnson & Johnson (JNJ)2.8$163.07-0.4%2.60%24.52Buy$189.75
Compare These Stocks  Add These Stocks to My Watchlist 

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.